Net Loss Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Abstract]

Net Loss Per Share

Note 19 — Net Loss Per Share

The respective “Net loss per share - attributable to PAVmed Inc. - basic and diluted” and “Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted” - for the periods indicated - is as follows:

	Year Ended December 31,
	2021			2020
Numerator
Net loss - before noncontrolling interest	$	(56,126	)	$	(35,888	)
Net loss attributable to noncontrolling interest		5,779			1,612
Net loss - as reported, attributable to PAVmed Inc.	$	(50,347	)	$	(34,276	)
Series B Convertible Preferred Stock dividends – earned(1)	$	(283	)	$	(287	)
Net loss attributable to PAVmed Inc. common stockholders	$	(50,630	)	$	(34,563	)
Denominator
Weighted average common shares outstanding, basic and diluted(2)		77,515,767			47,432,115
Loss per share
Basic and diluted
Net loss - as reported, attributable to PAVmed Inc.	$	(0.65	)	$	(0.72	)
Net loss attributable to PAVmed Inc. common stockholders	$	(0.65	)	$	(0.73	)

The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows:

The Series B Convertible Preferred Stock dividends earned as of the each of the respective periods noted, are included in the calculation of basic and diluted net loss attributable to PAVmed Inc. common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors.

Basic weighted-average number of shares of common stock outstanding for the years ended December 31, 2021 and 2020 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all periods presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows:

	Year Ended December 31,
	2021		2020
PAVmed Inc. 2014 Equity Plan stock options and restricted stock awards		10,386,864		8,215,195
Unit purchase options - as to shares of common stock		—		53,000
Unit purchase options - as to shares underlying Series Z Warrants		—		53,000
Series Z Warrants		11,937,455		16,814,939
Series W Warrants		377,873		381,818
Series B Convertible Preferred Stock		1,113,919		1,228,075
Total		23,816,111		26,746,027